Chemotherapy With cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for hodgkin disease: Fourteen‐year follow‐up results

Kathryn E Dusenbery, Bruce A Peterson, Clara D. Bloomfield

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Thirty‐eight patients with advanced Hodgkin disease were treated with a combination of cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) from 1970 to 1973 and followed prospectively. Long‐term results after a median follow‐up of 14 years are reported. Seventeen of the 28 complete responders (61%) survived more than 10 years from the initiation of chemotherapy. At the current time, 12 of the 28 patients (43%) are continuously disease‐free 12.8 to 15.3 years after completing induction chemotherapy. Two additional patients are alive in third and fifth remissions. All relapses occurred within 5.5 years of completing induction chemotherapy. Late complications included sterility, aseptic osteonecrosis, severe pulmonary fibrosis, and chronic uveitis. Four of the complete responders (14%) developed second neoplasms, including acute myelogenous leukemia, non‐Hodgkin lymphoma and small cell carcinoma of the lung. All second malignancies were fatal and developed 5‐13 years after initiation of induction chemotherapy. Our data confirm that cure is possible with alternative regimens to MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone).

Original languageEnglish (US)
Pages (from-to)246-251
Number of pages6
JournalAmerican Journal of Hematology
Volume28
Issue number4
DOIs
StatePublished - Aug 1988

Keywords

  • combination chemotherapy
  • complications
  • cure

Fingerprint Dive into the research topics of 'Chemotherapy With cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for hodgkin disease: Fourteen‐year follow‐up results'. Together they form a unique fingerprint.

Cite this